Argireline (Acetyl Hexapeptide-8)
A topical peptide that aims to soften expression lines by interfering with the neurotransmitter release that drives muscle contraction.
Written by Anthivera EditorialPending medical review
Updated Regulatory status verified September 1, 2026
Cosmetic ingredient
Relevance for women
Marketed as 'needle-free Botox' for forehead and eye expression lines. Small studies — often 10% concentrations, frequently manufacturer-funded — report modest reductions in wrinkle depth. The effect is far milder than injectable botulinum toxin and limited by how little crosses the skin barrier. A cosmetic ingredient, not a drug.
Where the evidence sits
Anthivera’s calibrated five-tier scale — what the strongest evidence on Argireline (Acetyl Hexapeptide-8) actually supports today.
- Preclinical
- Limited clinicalArgireline
- Multiple human studies
- Phase 3
- FDA-approved
Limited clinical: Small open-label or case-report data in humans.
Questions to bring to a consult
- 01What evidence is there for Argireline (Acetyl Hexapeptide-8) in women specifically — and does that include perimenopausal or postmenopausal cohorts?
- 02What is the current FDA regulatory status, and which compounding pharmacy will my prescription go through?
- 03What baseline labs do you require before starting, and how often do you monitor?
- 04What are the realistic timelines and what does “not working for you” look like in practice?